Willis Towers Watson Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 3% organic growth, 22.3% adjusted margin, and 19% EPS growth, with AI and tech investments driving efficiency. Guidance remains for mid-single-digit growth and margin expansion, despite Middle East headwinds and competitive pricing.
Fiscal Year 2025
-
Strong Q4 and full-year results were driven by strategic focus, talent investment, and portfolio optimization, with 6% organic growth in Q4 and 5% for the year. Margin expansion, robust segment performance, and disciplined capital allocation support a positive 2026 outlook.
-
The acquisition expands reach in the U.S. middle market and specialty sectors, enhances technology capabilities, and is structured for strong financial returns. Cost synergies of $35 million are expected by 2028, with integration led by an experienced team and a focus on talent retention.
-
Q3 2025 saw 5% organic revenue growth, 230 bps margin expansion, and 11% higher adjusted EPS. Both HWC and R&B segments delivered strong results, with continued investments in technology and talent supporting growth and efficiency. Free cash flow and shareholder returns increased.
-
Q2 2025 saw 5% organic revenue growth, 150 bps margin expansion, and 20% higher adjusted EPS year-over-year. Both HWC and R&B segments delivered strong results, with robust pipelines and margin expansion expected for the full year. AI and technology investments are driving efficiency and growth.
-
Q1 2025 saw 5% organic revenue growth, 100 bps margin expansion, and $3.13 adjusted EPS, with strong performance in both HWC and R&B segments. The outlook for 2025 remains positive, with mid-single-digit growth and margin expansion expected, supported by recurring revenues, new client wins, and ongoing efficiency initiatives.
Fiscal Year 2024
-
Delivered strong 2024 results with 5% organic revenue growth and 17% adjusted EPS growth, driven by strategic transformation and margin expansion. Completed Tranzact divestiture and launched a reinsurance JV, positioning for continued growth, margin improvement, and $1.5B in share repurchases in 2025.
-
A refreshed strategy focuses on accelerating growth, enhancing efficiency, and optimizing the portfolio, with disciplined M&A and innovation in broking and health. Financial targets include mid-single-digit organic growth, annual margin expansion, and improved free cash flow, supported by ongoing transformation and technology investments.
-
Q3 2024 saw 6% organic revenue growth, 10% in Risk & Broking, and 4% in HWC, with adjusted EPS up 31% year-over-year. The sale of Transact simplifies the portfolio and is expected to boost margins and free cash flow, while share repurchase guidance was raised to $900 million.
-
Q2 2024 saw 6% organic revenue growth, 240 bps margin expansion, and 24% higher adjusted EPS. Guidance for 2024 was raised, with transformation savings and strategic hires fueling growth. R&B and Health segments led performance, while free cash flow and shareholder returns remained strong.